Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Introduction of biosimilars for the rheumatology drug adalimumab ... could dissuade most prescribers from switching. Another example (and perhaps driver) of that latter success came in June ...

Selarsdi is the second biosimilar to receive approval under a partnership between Iceland's Alvotech and Israel's Teva. Stelara is J&J’s best-selling drug, generating sales of around $10.9B in 2023.

Teva Pharmaceuticals and Alvotech last Friday launched Selarsdi, a biosimilar to Stelara. The Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only ...